ArticleMolecular biology reports2025
Tirzepatide improves neutrophilic inflammation in obese asthmatic mice by downregulating Th17 cell differentiation.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAsthma is a chronic respiratory disease affecting more than 330 million people worldwide. Obesity not only increases the risk of asthma attacks but also worsens symptoms and diminishes responsiveness to standard drug treatments. Tirzepatide, a dual GIP and GLP-1 receptor agonist, has demonstrated superior glycemic control and weight loss effects compared to selective GLP-1 receptor agonists in clinical trials. However, its impact on neutrophilic inflammation in obese asthmatic mice and the underlying molecular mechanisms remain unclear.
methodsThis study first established an obese mice model using a high-fat diet, followed by ovalbumin (OVA) sensitization and challenge to induce asthma. Glucose tolerance was assessed via oral glucose tolerance tests (OGTT), while body weight and blood glucose levels were monitored regularly. Pathological changes in lung tissue were evaluated using H&E and Masson’s trichrome staining. Serum leptin and insulin concentrations were measured by ELISA, and gene and protein expression levels were analyzed by qRT-PCR and Western blot, respectively. Additionally, the proportions of Th17 cells and neutrophils were determined by flow cytometry, and neutrophil migration was assessed through Transwell assays.
resultsObesity exacerbates neutrophilic inflammation and asthma pathology in mice. Tirzepatide reduced airway inflammation and neutrophil aggregation in obese asthmatic mice by inhibiting the Notch signaling pathway, which in turn decreased the differentiation of Th17 cells. Both in vivo and in vitro experiments demonstrated that Tirzepatide suppresses the Notch signaling pathway, thereby reducing neutrophil recruitment mediated by Th17 cells.
conclusionThis study demonstrates that obesity-induced Th17 differentiation exacerbates neutrophilic inflammation in asthmatic mice. Tirzepatide reduces neutrophilic inflammation in obese asthmatic mice by inhibiting the NOTCH signaling pathway and suppressing Th17 differentiation. These findings offer new insights for the clinical treatment of obesity-related asthma.
Indexed as
Identifiers
41389087What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.